Skip to main content
SpringerLink
Log in

A phase I and pharmacokinetic trial of terephthalamidine (NSC 57155) as a 120-hour continuous infusion

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

In this phase I study, terephthalamidine was administered as a 120-hour continuous infusion repeated every 21 days. Thirteen patients received 27 courses of terephthalamidine at four dose levels (14, 28, 46, and 70 mg/m2/day). Dose-limiting toxicity consisted of profound and intractable anorexia, weight loss and prostration in all patients. Toxicity was delayed and accompanied by hyponatremia and hypokalemia. No hematologic or other toxicity was documented. One patient with adenocarcinoma of the lung had a 40% decrease in mediastinal lymph nodes and resolution of a pleural effusion lasting 2 months. Pharmacokinetic analysis by HPLC was performed in all patients during their first course. The harmonic mean terminal half-life for terephthalamidine was 23 hours with a plasma clearance of 1.7 l/hr/m2. Both plasma concentrations achieved during infusion (r2 = 0.9) and area under the curve (AUC) (r2 = 0.8) were proportional to increase in dose (p < 0.002). Renal excretion accounted for 64% of the total cumulative dose, with an average renal clearance of 1.16 l/hr/m2. Due to the unacceptable toxicity seen at all doses with this schedule, no further studies are recommended unless the mechanism of toxicity is better understood and can be prevented.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hirt R, Berchtold R: Biophysical studies with synthetic lecithin as a road to new chemotherapeutic agents. Cancer Chemother Rep 18:5-7, 1962

    Google Scholar 

  2. Lyman M, Wollner N, Ellison RR, Krakoff I, Frei E, III, Close H, Burchenal JH: Effects of NSC 38,280 in man (abstract). Proc Am Assoc Cancer Res 3:340, 1962 (#165)

    Google Scholar 

  3. Louis J, Taylor H, Sutow W: Phase I evaluation of terephthalamidine (N′N″-bis[p-(N" methylamidino)phenyl]-tetrahydrochloride, trihydrate) NSC 57155 (abstract). Proc Am Assoc Cancer Res 4:40, 1963 (#155)

    Google Scholar 

  4. Louis J, Taylor HG, Sutow WW, Bersagel DE, Griffith KM: Phase I evaluation of 4′,4″-di-2-imidazolin-2-ylterephthalanilide dihydrochloride (NSC 35843). Cancer Chem Rep 23:51-54, 1962

    Google Scholar 

  5. Kensler CJ, Palm PE, Day HM, Battista SP, Rogers WI, Yesair DW, Wodinsky I: Toxicology of antileukemic agents with special reference to phthalanilide derivatives. Cancer Res 25:1622-1637, 1965

    Google Scholar 

  6. Yesair DW, Kensler CJ: The phthalanilides. In: Sartorelli AC and Johns DG (eds) Antineoplastic and Immunosuppressive Agents, Vol 38, Pt II, Handbook of Experimental Pharmacology, Springer-Verlag, Berlin 1974, pp 820-828

    Google Scholar 

  7. Sivak A, Rogers WL, Wodinsky I, Kensler CJ: Distribution and effect of 4′,4″-di(2-imidazolin-2-yl) terephthalanilide dihydrochloride hemihydrate and its 2-chloro analogue in lymphocytic leukemias L1210 and P388. J Natl Cancer Inst 33:347-465, 1964

    Google Scholar 

  8. Yesair DW, Kohner FA, Rogers WI, Baranowsky PE, Kensler CJ: Relationship of phthalanilide-lipid complexes to uptake and retention of 2-chloro-4″4″-di(2-imidazolin-2-yl)terephthalanilide (NSC 60339) by sensitive and resistant P388 leukemia cells. Cancer Res 26:202-207, 1966

    Google Scholar 

  9. Kensler CJ: Chemotherapeutic activity of phthalanilide derivatives: an approach to anticodic therapy? Cancer Res 23:1353- 1363, 1963

    Google Scholar 

  10. Pine MJ, Harzewski E, Wissler FC: Studies on the delayed toxicity of phthalanilides an other compounds. Toxicol Appli Pharmacol 7:494, 1965

    Google Scholar 

  11. Booth J, Boyland E, Gellhorn A: Search for metabolites of anti-leukemic phthalanilides, 2-chloro-4′4″-di(2-imidazolin-2-yl)terephthalanilide (NSC 60339) and 2-amino-4′4″-di(2-imidazolin-2-yl)terephthalanilide dihydrochloride (NSC 50449). Cancer Chemother Rep 43:11-18, 1964

    Google Scholar 

  12. Ochoa M Jr, Gellhorn A, Benjamin WB: Phthalanilide inhibition of protein synthesis in a cell free L1210 mouse ascites leukemia system. Cancer Res 24:480-484, 1964

    Google Scholar 

  13. Kreis W, Ellison RR, Lyman MS, Burchenal JH, Block R, Warketin DL: Clinical investigation of the physiologic disposition of a phthalanilide (NSC 38280) and phthalanilide derivative (NSC 57155) in 7 patients. Cancer Res 25:402-407, 1965

    Google Scholar 

  14. Jondorf WR, Spector A, Chaiken SJ: The effects of two carcinostatic agents on the chemically induced stimulation of amino acid incorporation in a mammalian system. Biochem Biophys Res Commun 20:787-792, 1965

    Google Scholar 

  15. Sivak A, Mahoney AJ, Rogers WI: Studies in the intracellular localization and effects of 2-chloro-4′4″-di(2-imidazolin-2-yl)terephthalanilide on mitochondria from P388 lymphocytic leukemia and rat liver. Biochem Pharmacol 16:1919-1931, 1967

    Google Scholar 

  16. Yesair DW, Rogers WI, Baronowsky PE, Wodinsky I, Thayer PS, Kensler CJ: Relationship of uptake and binding of an antileukemic phthalanilide to its biochemical and chemotherapeutic effects on P388 lymphocytic leukemia cells. Cancer Res 27:314-321, 1967

    Google Scholar 

  17. Burchenal JH: Present status of the terephthalanilides II. Studies on the mechanism of antileukemic action. In Plattner PA (ed) Chemotherapy of Cancer, Elsevier Publishing Company, Amsterdam 1964, pp 233-239

    Google Scholar 

  18. Sivak A, Rogers WI, Wodinsky I, Kensler CJ: Studies on the formation of phthalanilide-deoxyribonucleic acid complexes and their relationship to chemotherapeutic activity. Cancer Res 25:902-909, 1965

    Google Scholar 

  19. Fisherman JS, Cline EM, Plowman J, Quinn FR, Hawkins MJ: Terephthalamidine: Past and future. Invest New Drugs 9(4):295-303, 1991

    Google Scholar 

  20. Johnson RK, Faurette LF, Clement JJ, Burchenal JH: Detailed evaluation of NSC 57155 in tumor bearing mice (abstract). Proc Am Assoc Cancer Res 23:325, 1983

    Google Scholar 

  21. Nadkami MV, Davis RD, Rakieten ML, Rakieten N, Frances S: Phthalanilides - A summary of toxicologic observations in experimental animals. Cancer Chemother Rep 19:31-40, 1962

    Google Scholar 

  22. Bionetics Research Laboratories Inc, Falls Church VA: Subchronic parenteral infusion studies in monkeys of NSC 57155-terephthalamidine, N, N″-bis[p-N′-methylamidino)phenyl]-, tetrahydrochloride, trihydrate. Final report to Cancer Chemotherapy National Service Center. December 14, 1962

  23. Waud WR, Hill BL: High-performance liquid chromatography determination of terephthalamidine in plasma. J Chromatogr 425:220-226, 1988

    Google Scholar 

  24. Gibaldi M: Biopharmaceutics and clinical pharmacokinetics, Ed 3. Lea and Febiger, Philadelphia 1984, pp 17-18

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The University of Texas Health Science Center at San Antonio, San Antonio, Texas

    Gladys I. Rodriguez, John G. Kuhn, Geoffrey Weiss, Pearl De La Cruz, Pamela New, John R. Eckardt, Gary M. Clark, Susan G. Hilsenbeck & Daniel D. Von Hoff

  2. Cancer Therapy and Research Center of South Texas, San Antonio, Texas, U.S.A

    Gladys I. Rodriguez, Suzanne M. Fields, John R. Eckardt, Liz Campbell, Gary M. Clark & Daniel D. Von Hoff

Authors
  1. Gladys I. Rodriguez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John G. Kuhn
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Geoffrey Weiss
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pearl De La Cruz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Pamela New
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Suzanne M. Fields
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. John R. Eckardt
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Liz Campbell
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Gary M. Clark
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Susan G. Hilsenbeck
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Daniel D. Von Hoff
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rodriguez, G.I., Kuhn, J.G., Weiss, G. et al. A phase I and pharmacokinetic trial of terephthalamidine (NSC 57155) as a 120-hour continuous infusion. Invest New Drugs 16, 57–67 (1998). https://doi.org/10.1023/A:1006003718255

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006003718255

Search

Navigation